Partial
Not Aligned
Patient Risk:
Medium
Summary
Several claims align with the label (indication, underarm topical use, mechanism), and some safety statements are supported (dry mouth, headache, local skin reactions). However, there are major inaccuracies/unsupported elements including the wrong active ingredient/class (clonidine and alpha-2 agonist), incorrect adverse-effect set (upper respiratory tract infections, fatigue), and incorrect manufacturing/approval date claims, plus an overbroad/unsupported explanation of how it works.
Category Scores
Accurate Statements
Qbrexza is applied topically to the underarms.
Dosage and Administration: 'for topical use in the underarm area only' and 'apply ... on the underarm areas only.'
Qbrexza (clonidine topical) is a prescription medication used to treat the symptoms of moderate to severe primary axillary hyperhidrosis.
Indications and Usage: indicated for 'topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.' (Note: label wording does not specify 'moderate to severe' or 'symptoms.')
Common side effects of Qbrexza can include dryness of the mouth.
Adverse Reactions (Clinical Trials): 'dry mouth' listed among adverse reactions reported ≥2%.
Common side effects of Qbrexza can include headache.
Adverse Reactions (Clinical Trials): 'headache' listed among adverse reactions reported ≥2%.
Some patients may experience localized skin reactions where Qbrexza is applied.
Adverse Reactions (Clinical Trials): Table 2 local skin reactions including 'erythema, burning/stinging, pruritus' (relatively common in both groups).
Qbrexza is an alpha-2 adrenergic receptor agonist.
Mechanism of Action section states glycopyrronium is a competitive inhibitor of acetylcholine receptors, not an alpha-2 agonist. (Thus this statement is not supported.)
Unsupported Statements
Qbrexza (clonidine topical) is a prescription medication used to treat the symptoms of moderate to severe primary axillary hyperhidrosis.
Label does not state 'clonidine' or 'alpha-2' (see contraindication/mechanism mismatches). Label also does not specify 'moderate to severe' or the phrase 'treat the symptoms'—it states indication for topical treatment of primary axillary hyperhidrosis.
Qbrexza is manufactured by Lytix Biopharma AS.
No label content provided/quoted here supports the manufacturer claim.
The FDA approved Qbrexza in July 2015.
No label excerpt provided includes FDA approval date.
Qbrexza is an alpha-2 adrenergic receptor agonist.
Mechanism of Action states glycopyrronium is a competitive inhibitor of acetylcholine receptors on peripheral tissues including sweat glands.
When applied to the skin, Qbrexza is absorbed.
Provided label excerpts do not explicitly state absorption.
Qbrexza is believed to work by inhibiting signaling pathways that stimulate sweat production in the sweat glands.
Label describes inhibition of acetylcholine action on sweat glands; the 'signaling pathways' phrasing is not directly supported by the provided label text.
Common side effects of Qbrexza can include upper respiratory tract infections.
Provided label adverse reaction examples include dry mouth, mydriasis, oropharyngeal pain, headache, urinary hesitation, vision blurred, nasal dryness, dry throat, dry eye, dry skin, constipation; 'upper respiratory tract infections' is not supported.
Common side effects of Qbrexza can include fatigue.
Provided label adverse reaction examples do not list fatigue.
Other topical treatments for hyperhidrosis primarily consist of antiperspirants containing aluminum chloride compounds.
No label excerpt supports this comparative therapy statement.
Antiperspirants work by physically blocking sweat ducts.
No label excerpt supports this mechanism comparison statement.
Contradictions
High
AI Statement
Qbrexza (clonidine topical) is a prescription medication used to treat the symptoms of moderate to severe primary axillary hyperhidrosis.
Label Reference
Drug identity/Mechanism: label describes glycopyrronium (not clonidine) mechanism as acetylcholine receptor inhibition on sweat glands.
High
AI Statement
Qbrexza is an alpha-2 adrenergic receptor agonist.
Label Reference
Clinical Pharmacology (Mechanism of Action): 'Glycopyrronium is a competitive inhibitor of acetylcholine receptors... In hyperhidrosis, glycopyrronium inhibits the action of acetylcholine on sweat glands.'
Important Omissions
Indication specifics and age limitation: Qbrexza is indicated for primary axillary hyperhidrosis in adults and pediatric patients 9 years and older.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Major inaccuracies about drug identity/class (clonidine, alpha-2 agonist) and unsupported adverse effects could misinform risk profile; however, some safety-relevant adverse effects (dry mouth, headache) and local skin reactions are consistent with label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Incorrect drug identity/mechanism claims (clonidine; alpha-2 adrenergic agonist) and unsupported adverse effects/comparative therapy statements.
Suggested Improvement
Replace clonidine/alpha-2 agonist claims with label-supported glycopyrronium mechanism (competitive acetylcholine receptor inhibition on sweat glands). Limit adverse-effect lists to those shown in the label (e.g., dry mouth, headache; consider local skin reactions). Remove unsupported manufacturer/approval-date comparisons unless directly supported by the provided label text.